Lv11
30 积分 2025-10-12 加入
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study
1小时前
已完结
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies
7天前
已关闭
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies
8天前
已完结
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
8天前
已完结
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
26天前
已完结
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model
27天前
已完结
Appraisal of Clinical Practice Guideline: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
28天前
已完结
Clinical and biological advances of critical complications in acute myeloid leukemia
29天前
已完结
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis
29天前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
1个月前
已完结
皖公网安备34019202002308
